止血剤の市場規模、シェア、成長分析、タイプ別、治療法別、エンドユーザー別、地域別 - 産業予測、2025～2032年

止血剤の世界市場規模は、2023年に73億8,000万米ドルと評価され、2024年の80億3,000万米ドルから2032年には157億7,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは8.8％で成長する見通しです。

止血剤市場は、特に高齢化社会における出血性疾患や慢性疾患の有病率の増加により、大きな成長が見込まれています。世界の外科手術の急増は、高度な止血薬に対する需要をさらに増大させています。世界保健機関（WHO）によると、年間125万件以上の交通事故が重篤な出血の原因となっており、こうした薬剤の差し迫った必要性が浮き彫りになっています。さらに、ロボット支援手術のような手術手技の進歩も、市場の需要をさらに押し上げると思われます。しかし、高い手術費用、不利な償還政策、発展途上地域における最近の技術革新に対する認識不足などの課題が、成長を阻害する可能性があります。こうしたハードルに対処することは、市場の潜在力を最大限に活用する上で極めて重要です。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 主要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

止血剤市場規模：タイプ別

• 市場概要
• トロンビンベースの止血剤
• ゼラチンベースの止血剤
• コラーゲンベースの止血剤
• 酸化再生セルロース系止血剤
• フィブリンシーラント
• その他

止血剤市場規模：治療別

• 市場概要
• 心臓血管
• 一般外科
• 消化器外科
• 脳神経外科
• その他

止血剤市場規模：エンドユーザー別

• 市場概要
• 病院
• 外科センター
• 老人ホーム
• その他

止血剤市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Baxter International Inc.（USA）
• Becton, Dickinson and Company（USA）
• Medtronic plc（Ireland）
• Stryker Corporation（USA）
• Sanofi S.A.（France）
• CSL Limited（Australia）
• Zimmer Biomet Holdings, Inc.（USA）
• Teleflex Incorporated（USA）
• CryoLife, Inc.（USA）
• Integra LifeSciences Holdings Corporation（USA）
• Mallinckrodt Pharmaceuticals（UK）
• B. Braun Melsungen AG（Germany）
• Terumo Corporation（Japan）
• Smith & Nephew plc（UK）
• Haemonetics Corporation（USA）
• Ethicon, Inc.（USA）
• The Medicines Company（USA）
• Anika Therapeutics, Inc.（USA）

結論と推奨事項

Global Hemostatic Agents Market size was valued at USD 7.38 billion in 2023 and is poised to grow from USD 8.03 billion in 2024 to USD 15.77 billion by 2032, growing at a CAGR of 8.8% during the forecast period (2025-2032).

The Hemostatic Agents Market is poised for significant growth due to the increasing prevalence of bleeding disorders and chronic diseases, particularly among the aging population. The surge in surgical procedures worldwide further amplifies demand for advanced hemostasis medications. According to the World Health Organization, over 1.25 million road injury incidents annually contribute to severe bleeding, highlighting a pressing need for these agents. Additionally, advancements in surgical techniques, such as robotic-assisted surgeries, will likely drive further market demand. However, challenges such as high surgical costs, unfavorable reimbursement policies, and a lack of awareness about recent technological innovations in developing regions may impede growth. Addressing these hurdles will be crucial for harnessing the market's full potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemostatic Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemostatic Agents Market Segmental Analysis

Global Hemostatic Agents Market is segmented by Type, Treatment, End User and region. Based on Type, the market is segmented into Thrombin Based Hemostats, Gelatin Based Hemostats, Collagen Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Combination Hemostats, Fibrin Sealants and Others. Based on Treatment, the market is segmented into Cardiovascular, General Surgery, Digestive Surgery, Neurosurgery and Others. Based on End User, the market is segmented into Hospitals, Surgery Centers, Nursing Homes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemostatic Agents Market

The global hemostatic agents market is primarily driven by the increasing frequency of surgical procedures worldwide, which has heightened the need for effective bleeding management during operations. As the number of surgeries rises, so does the incidence of bleeding complications, underscoring the importance of hemostatic products in clinical practice. Significant advancements in medical devices have enhanced the ability to achieve hemostasis, further propelling market growth. Recent data from the National Center for Biotechnology Information (NCBI) indicates that approximately 60-70% of transfused red blood cells are utilized in surgical settings, emphasizing the critical role these agents play in minimizing surgical risks and optimizing patient outcomes.

Restraints in the Global Hemostatic Agents Market

The Global Hemostatic Agents market faces several constraints that hinder its growth. One significant issue is the occurrence of uncontrolled bleeding, which poses a challenge in the widespread adoption of these agents. Although advancements have led to improved management of bleeding during surgeries and reduced infection risks, the high cost of these products remains a barrier to their utilization. Furthermore, specific surgical instruments may only be compatible with certain hemostatic agents, creating additional clinical limitations. Despite technological progress, these constraints continue to restrict the effective application of hemostatic agents in various medical scenarios, hampering their market potential.

Market Trends of the Global Hemostatic Agents Market

The Global Hemostatic Agents market is witnessing a significant trend driven by the escalating need to address hemorrhage, a leading cause of mortality in both military and civilian populations. With over 30% of traumatic deaths resulting from uncontrolled bleeding, the demand for effective hemostatic agents is surging, particularly in emergency and high-stress medical environments. These agents not only stabilize patients by mitigating risks associated with hypothermia, infections, and organ failure but also play a crucial role in trauma care. As awareness of their life-saving potential grows, investment in research and development is likely to further propel market expansion and innovation in hemostatic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemostatic Agents Market Size by Type & CAGR (2025-2032)

• Market Overview
• Thrombin Based Hemostats
• Gelatin Based Hemostats
• Collagen Based Hemostats
• Oxidized Regenerated Cellulose Based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

Global Hemostatic Agents Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Cardiovascular
• General Surgery
• Digestive Surgery
• Neurosurgery
• Others

Global Hemostatic Agents Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Surgery Centers
• Nursing Homes
• Others

Global Hemostatic Agents Market Size & CAGR (2025-2032)

• North America (Type, Treatment, End User)
  • US
  • Canada
• Europe (Type, Treatment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stryker Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teleflex Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CryoLife, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences Holdings Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smith & Nephew plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ethicon, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• The Medicines Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anika Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations